SLC5A2 and chronic kidney disease: This cohort study compares anemia incidence between sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with type 2 diabetes and chronic kidney disease (CKD) stages 1 to 3 in Taiwan.